General
Preferred name
zanzalintinib
Synonyms
CL-092 ()
JUN04542 ()
XL092 ()
XL 092 ()
XL-092 ()
ZANZALINTINIB FUMARATE ()
Xl 092 ()
XL-092 FUMARATE ()
Zanzalintinib hemifumarate ()
XL092 fumarate ()
P&D ID
PD157786
CAS
2367004-54-2
Tags
available
drug candidate
Drug indication
Neoplasm
Solid tumour/cancer
Drug Status
investigational
Max Phase
1.0
3.0
Structure
Probe scores
P&D probe-likeness score
[[ v.score ]]%
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
DESCRIPTION We obtained the chemical structure for zanzalintinib from the WHO's proposed INN list 127 (21 July 2022). In this document it was described as a tyrosine kinase inhibitor and antineoplastic. The synonym list in PubChem's record for this compound suggests that zanzalintinib is the INN for Exelixis's clinical lead XL092 which is an analogue of . XL092 is an ATP-competitive inhibitor of multiple RTKs including MET, VEGFR2, AXL and MER . (GtoPdb)
DESCRIPTION Zanzalintinib (XL092) is an orally active, ATP-competitive inhibitor of multiple receptor tyrosine kinases (RTKs) including MET, VEGFR2, AXL and MER, with IC50s in cell-based assays of 15 nM, 1.6 nM, 3.4 nM, 7.2 nM respectively. Zanzalintinib exhibits anti-tumor activity. Zanzalintinib has the potential for kinase-dependent diseases and conditions research[1][2].
PRICE 75
DESCRIPTION XL092 (JUN04542) is an Axl Mer cMet KDR inhibitor for the treatment of Axl and Mer receptor tyrosine kinase- dependent disorders. (TargetMol Bioactive Compound Library)
Compound Sets
9
Cayman Chemical Bioactives
37749
ChEMBL Drugs
CHEMBL5314428
CHEMBL5314605
DrugBank
DB17525
DrugMAP
DM3LRAC
Guide to Pharmacology
12093
MedChem Express Bioactive Compound Library
HY-138696
PKIDB
Selleckchem Bioactive Compound Library
xl092
TargetMol Bioactive Compound Library
T9052
External IDs
10
Properties
(calculated by RDKit )
Molecular Weight
528.18
Hydrogen Bond Acceptors
6
Hydrogen Bond Donors
3
Rotatable Bonds
8
Ring Count
5
Aromatic Ring Count
4
cLogP
4.89
TPSA
118.65
Fraction CSP3
0.17
Chiral centers
0.0
Largest ring
6.0
QED
0.28
Structural alerts
0
No structural alerts detected
Related compounds
Custom attributes
(extracted from source data)
Target
AXL
c-Met
c-Met/HGFR
KDR
Mer
TAM Receptor
VEGFR
Axl,c-Met,Mertk,VEGFR
Pathway
Angiogenesis
Tyrosine Kinase/Adaptors
Protein Tyrosine Kinase/RTK
Source data